



DFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-134-D)

In the Application of:)	
)	
Lavie et al.)	Group Art Unit: 1652
)	
Serial No. 10/791,155)	Before the Examiner:
)	
Filing Date: March 1, 2004)	
)	Confirmation No.: 3822
For: Use of Specifically Engineered)	
Enzymes to Enhance the Efficacy)	
of Prodrugs)	

TRANSMITTAL LETTER


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
 - a. Response to Restriction Requirement; and
 - b. Return Receipt Postcard
2. With respect to additional fees:
 - a. No fees are required.
3. Please charge any deficiency in the amount due, or credit any overpayment, to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as "First Class Mail" in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 21st day of July, 2005.

By:


Jason J. Derry
Reg. No. 50,692



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 02-134-D)

In the Application of:)	
)	
Lavie et al.)	Group Art Unit: 1652
)	
Serial No. 10/791,155)	Before the Examiner:
)	
Filing Date: March 1, 2004)	
)	Confirmation No.: 3822
For: Use of Specifically Engineered)	
Enzymes to Enhance the Efficacy)	
of Prodrugs)	

Mail Stop Amendment
Commissioner for Patents
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction Requirement mailed June 21, 2005, Applicants elect group I (claims 1-16 and 69) with traverse. In addition, in response to the direction to elect species on page 4 of the Restriction Requirement, Applicants make the following elections:

- A. SEQ ID NO: 5,
- B. leukemia,
- C. antibody for CD33, and
- D. the nucleoside analog AraC for examination.

Also, Applicants respectfully request that the following amendments to the claims be entered.